The Experts below are selected from a list of 24651 Experts worldwide ranked by ideXlab platform

Michele Maio - One of the best experts on this subject based on the ideXlab platform.

  • highlights on endoglin cd105 from basic findings towards clinical applications in human cancer
    Journal of Translational Medicine, 2004
    Co-Authors: Ester Fonsatti, Michele Maio
    Abstract:

    Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific Cell Membrane Marker for endothelial Cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a Cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial Cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed.

  • Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer
    Journal of Translational Medicine, 2004
    Co-Authors: Ester Fonsatti, Michele Maio
    Abstract:

    Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific Cell Membrane Marker for endothelial Cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a Cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial Cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed.

Ester Fonsatti - One of the best experts on this subject based on the ideXlab platform.

  • highlights on endoglin cd105 from basic findings towards clinical applications in human cancer
    Journal of Translational Medicine, 2004
    Co-Authors: Ester Fonsatti, Michele Maio
    Abstract:

    Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific Cell Membrane Marker for endothelial Cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a Cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial Cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed.

  • Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer
    Journal of Translational Medicine, 2004
    Co-Authors: Ester Fonsatti, Michele Maio
    Abstract:

    Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific Cell Membrane Marker for endothelial Cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a Cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial Cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed.

Armand Bensussan - One of the best experts on this subject based on the ideXlab platform.

  • cd4 cutaneous t Cell lymphoma Cells express the p140 killer Cell immunoglobulin like receptor
    Blood, 2001
    Co-Authors: Martine Bagot, A Moretta, Simona Sivori, Roberto Biassoni, Claudia Cantoni, Cristina Bottino, Laurence Boumsell, Armand Bensussan
    Abstract:

    Tumor Cells of patients with cutaneous T-Cell lymphoma (CTCL) have the Cell surface phenotype of mature T-helper lymphocytes, and it may be impossible to differentiate them from nonmalignant lymphocytes in skin and blood. Until now, no specific Cell Membrane Marker of CTCL has been reported. In the current study, it is reported for the first time that CTCL Cells express the major histocompatibility complex class I binding p140–killer Cell immunoglobulin-like receptor, which has been described on a minor subset of natural killer lymphocytes and on a marginal circulating CD8+ T lymphocyte subset. Interestingly, the molecular characterization of this KIR expressed by CTCL allowed us to isolate a novel allelic form of p140–KIR3DL, resulting in 4 amino acid substitutions, 3 in the extraCellular immunoglobulin-like domain of the protein and one in the cytoplasmic region. This finding is likely to be important both for the pathophysiology and for the clinical treatment of patients with CTCL.

  • CD4+ cutaneous T-Cell lymphoma Cells express the p140–killer Cell immunoglobulin-like receptor
    Blood, 2001
    Co-Authors: Martine Bagot, A Moretta, Simona Sivori, Roberto Biassoni, Claudia Cantoni, Cristina Bottino, Laurence Boumsell, Armand Bensussan
    Abstract:

    Tumor Cells of patients with cutaneous T-Cell lymphoma (CTCL) have the Cell surface phenotype of mature T-helper lymphocytes, and it may be impossible to differentiate them from nonmalignant lymphocytes in skin and blood. Until now, no specific Cell Membrane Marker of CTCL has been reported. In the current study, it is reported for the first time that CTCL Cells express the major histocompatibility complex class I binding p140–killer Cell immunoglobulin-like receptor, which has been described on a minor subset of natural killer lymphocytes and on a marginal circulating CD8+ T lymphocyte subset. Interestingly, the molecular characterization of this KIR expressed by CTCL allowed us to isolate a novel allelic form of p140–KIR3DL, resulting in 4 amino acid substitutions, 3 in the extraCellular immunoglobulin-like domain of the protein and one in the cytoplasmic region. This finding is likely to be important both for the pathophysiology and for the clinical treatment of patients with CTCL.

Fang Wei - One of the best experts on this subject based on the ideXlab platform.

  • Anti-CD133 monoclonal antibody conjugated immunomagnetic nanosensor for molecular imaging of targeted cancer stem Cells
    Sensors and Actuators B: Chemical, 2018
    Co-Authors: Xueqin Wang, Yan Yang, Huiru Zhang, Baoming Tian, Liuqing Cui, Haibo Weng, Fang Wei
    Abstract:

    Abstract Magnetic nanosensors are considered as highly attractive platforms for effective treatments in cancer diagnosis and therapy. Herein a smart immunomagnetic nanosensor is novelly developed for molecular imaging of targeted glioblastoma cancer stem Cells (CSCs), based on specific interaction between Cell-Membrane Marker antigen CD133 of glioblastoma CSCs and its raised anti-CD133 monoclonal antibody (mAb). Superparamagnetic iron oxide (SPIO) γ-Fe 2 O 3 nanoparticles (NPs) were fabricated as nanosensor cores with approximately 10–15 nm in size, and coated with carboxymethyl chitosan (CMCS) via sodium tripolyphosphate (TPP) crosslinking, and then chemically modified with polyethylenimine (PEI). Anti-CD133 mAb, specific affinity with the cancer stem bioMarker CD133 expressed on the Membrane surface of glioblastoma CSCs, was subsequently conjugated with the PEI- modified SPIO NPs to form anti-CD133 mAb conjugated immunomagnetic nanosensor. The prepared immunomagnetic nanosensor i.e. anti-CD133 mAb-conjugated nanoscale magnetic sensor (mAb-nano-MSN) was biologically assayed with Cellular toxicity, Cell cycle and specificity, and finally delivered to the targeted CSCs for fluorescence imaging and magnetic resonance imaging (MRI) within human brain glioblastoma CSCs. The results demenstrated that the developed immunomagnetic nanosensor displayed preferable properties such as exCellent biocompatibility, non-toxicity and high specificity. The glioblastoma CSCs treated with anti-CD133 mAb-nano-MSN displayed a strong red fluorescence signal and a negative contrast enhancement compared with the Cells treated with non-mAb-functionalized magnetic nanopartitles, probably due to efficient endocytosis mediated by anti-CD133 mAb grafted onto the prepared magnetic nanosensor. Therefore, these results indicated the fabricated anti-CD133 mAb-nano-MSN could be used as a promising nanovehicle for molecular imaging for the targeted CSCs in human brain tumor diagnosis and therapy.

Martine Bagot - One of the best experts on this subject based on the ideXlab platform.

  • cd4 cutaneous t Cell lymphoma Cells express the p140 killer Cell immunoglobulin like receptor
    Blood, 2001
    Co-Authors: Martine Bagot, A Moretta, Simona Sivori, Roberto Biassoni, Claudia Cantoni, Cristina Bottino, Laurence Boumsell, Armand Bensussan
    Abstract:

    Tumor Cells of patients with cutaneous T-Cell lymphoma (CTCL) have the Cell surface phenotype of mature T-helper lymphocytes, and it may be impossible to differentiate them from nonmalignant lymphocytes in skin and blood. Until now, no specific Cell Membrane Marker of CTCL has been reported. In the current study, it is reported for the first time that CTCL Cells express the major histocompatibility complex class I binding p140–killer Cell immunoglobulin-like receptor, which has been described on a minor subset of natural killer lymphocytes and on a marginal circulating CD8+ T lymphocyte subset. Interestingly, the molecular characterization of this KIR expressed by CTCL allowed us to isolate a novel allelic form of p140–KIR3DL, resulting in 4 amino acid substitutions, 3 in the extraCellular immunoglobulin-like domain of the protein and one in the cytoplasmic region. This finding is likely to be important both for the pathophysiology and for the clinical treatment of patients with CTCL.

  • CD4+ cutaneous T-Cell lymphoma Cells express the p140–killer Cell immunoglobulin-like receptor
    Blood, 2001
    Co-Authors: Martine Bagot, A Moretta, Simona Sivori, Roberto Biassoni, Claudia Cantoni, Cristina Bottino, Laurence Boumsell, Armand Bensussan
    Abstract:

    Tumor Cells of patients with cutaneous T-Cell lymphoma (CTCL) have the Cell surface phenotype of mature T-helper lymphocytes, and it may be impossible to differentiate them from nonmalignant lymphocytes in skin and blood. Until now, no specific Cell Membrane Marker of CTCL has been reported. In the current study, it is reported for the first time that CTCL Cells express the major histocompatibility complex class I binding p140–killer Cell immunoglobulin-like receptor, which has been described on a minor subset of natural killer lymphocytes and on a marginal circulating CD8+ T lymphocyte subset. Interestingly, the molecular characterization of this KIR expressed by CTCL allowed us to isolate a novel allelic form of p140–KIR3DL, resulting in 4 amino acid substitutions, 3 in the extraCellular immunoglobulin-like domain of the protein and one in the cytoplasmic region. This finding is likely to be important both for the pathophysiology and for the clinical treatment of patients with CTCL.